Literature DB >> 9603478

VCAM-1 is internalized by a clathrin-related pathway in human endothelial cells but its alpha 4 beta 1 integrin counter-receptor remains associated with the plasma membrane in human T lymphocytes.

I Ricard1, M D Payet, G Dupuis.   

Abstract

Lymphocyte extravasation involves a step(s) of de-adhesion to allow trans- and subendothelial migration in response to inflammatory signals. We show here that ligated VCAM-1 was rapidly internalized (t1/2 14.5 min) in ECV 304 endothelial cells and in TNF-alpha-primed human umbilical vein-derived endothelial cells (t1/2 11.2 min). The process required energy (ATP), intracellular Ca2+, an intact cytoskeletal network and active protein kinases. The internalization of VCAM-1 involved a clathrin-dependent pathway based on the observations that 1) it was inhibited in cells treated with lysosomotropic agents or with a hypertonic concentration of sucrose, and 2) internalized VCAM-1 colocalized with clathrin. In contrast, the cross-linked alpha 4 beta 1 integrin counter-receptor of VCAM-1 remained associated with the plasma membrane of purified peripheral T and Jurkat cells. Our results suggest a model where VCAM-1 would initially participate in the retention of T cells to the endothelium by binding alpha 4 beta 1 integrin. Lymphocyte de-adhesion would be facilitated as a result of the internalization of VCAM-1. The persistent cell surface expression of alpha 4 beta 1 integrin would allow the migrating T cells to interact with and receive signal(s) from its fibronectin ligand of the extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603478     DOI: 10.1002/(SICI)1521-4141(199805)28:05<1708::AID-IMMU1708>3.0.CO;2-Y

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  17 in total

1.  In vivo detection of vascular adhesion protein-1 in experimental inflammation.

Authors:  K Jaakkola; T Nikula; R Holopainen; T Vähäsilta; M T Matikainen; M L Laukkanen; R Huupponen; L Halkola; L Nieminen; J Hiltunen; S Parviainen; M R Clark; J Knuuti; T Savunen; P Kääpä; L M Voipio-Pulkki; S Jalkanen
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells.

Authors:  H Yusuf-Makagiansar; T J Siahaan
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

Review 3.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

4.  Clustering endothelial E-selectin in clathrin-coated pits and lipid rafts enhances leukocyte adhesion under flow.

Authors:  Hendra Setiadi; Rodger P McEver
Journal:  Blood       Date:  2007-11-20       Impact factor: 22.113

5.  Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design.

Authors:  Peng H Tan; Shao-An Xue; Bin Wei; Angelika Holler; Ralf-Holger Voss; Andrew J T George
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

6.  Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells--a potential tool for specific drug delivery.

Authors:  Manuela Voinea; Ileana Manduteanu; Elena Dragomir; Monica Capraru; Maya Simionescu
Journal:  Pharm Res       Date:  2005-08-13       Impact factor: 4.200

7.  Diabetic LDL inhibits cell-cycle progression via STAT5B and p21(waf).

Authors:  Maria Felice Brizzi; Patrizia Dentelli; Marzia Pavan; Arturo Rosso; Roberto Gambino; Maria Grazia De Cesaris; Giovanni Garbarino; Giovanni Camussi; Gianfranco Pagano; Luigi Pegoraro
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

8.  Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes.

Authors:  Iason Papademetriou; Zois Tsinas; Janet Hsu; Silvia Muro
Journal:  J Control Release       Date:  2014-06-14       Impact factor: 9.776

Review 9.  Polymeric carriers: role of geometry in drug delivery.

Authors:  Eric A Simone; Thomas D Dziubla; Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2008-12       Impact factor: 6.648

10.  In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes.

Authors:  Timothy Wyant; Lili Yang; Eric Fedyk
Journal:  MAbs       Date:  2013 Nov-Dec       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.